menu
    • menu

    Find Oxycodone Hydrochloride manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 24
    Oxycodone Hydrochloride

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Oxycodone

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 124-90-3, Oxycodone hcl, Oxecta, Oxycontin, Endocodone, Roxicodone
    Molecular Formula
    C18H22ClNO4
    Molecular Weight
    351.8  g/mol
    InChI Key
    MUZQPDBAOYKNLO-RKXJKUSZSA-N
    FDA UNII
    C1ENJ2TE6C
    Oxycodone Hydrochloride
    A semisynthetic derivative of CODEINE.
    1 2D Structure

    Oxycodone Hydrochloride

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (4R,4aS,7aR,12bS)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride
    2.1.2 InChI
    InChI=1S/C18H21NO4.ClH/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10;/h3-4,13,16,21H,5-9H2,1-2H3;1H/t13-,16+,17+,18-;/m1./s1
    2.1.3 InChI Key
    MUZQPDBAOYKNLO-RKXJKUSZSA-N
    2.1.4 Canonical SMILES
    CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O.Cl
    2.1.5 Isomeric SMILES
    CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    C1ENJ2TE6C
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Dihydrohydroxycodeinone

    2. Dihydrone

    3. Dinarkon

    4. Eucodal

    5. Oxiconum

    6. Oxycodeinon

    7. Oxycodone

    8. Oxycone

    9. Oxycontin

    10. Pancodine

    11. Theocodin

    2.3.2 Depositor-Supplied Synonyms

    1. 124-90-3

    2. Oxycodone Hcl

    3. Oxecta

    4. Oxycontin

    5. Endocodone

    6. Roxicodone

    7. Oxycodone Hydrochloride Cii

    8. Chebi:7859

    9. 4,5alpha-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride

    10. (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydrochloride

    11. (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one;hydron;chloride

    12. Roxicodone (tn)

    13. Oxycontin (tn)

    14. (4r,4as,7ar,12bs)-4a-hydroxy-9-methoxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride

    15. Oxecta (tn)

    16. Roxybond

    17. Oxycodone Monohydrochloride

    18. Schembl30095

    19. Oxycodone Hydrochloride (usp)

    20. Chembl1200890

    21. Dtxsid80924674

    22. Oxycodone Hydrochloride [mi]

    23. Oxycodone Hydrochloride [usan]

    24. Akos024457896

    25. Oxycodone Hydrochloride [mart.]

    26. Oxycodone Hydrochloride [vandf]

    27. Anhydrous Oxycodone Hydrochloride

    28. Oxycodone Hydrochloride [who-dd]

    29. Oxycodone Hydrochloride, Analytical Standard

    30. Oxycodone Hydrochloride [orange Book]

    31. Oxycodone Hydrochloride Cii [usp-rs]

    32. Oxycodone Hydrochloride [ep Monograph]

    33. Tylox Component Oxycodone Hydrochloride

    34. C08026

    35. Codoxy Component Oxycodone Hydrochloride

    36. D00847

    37. Oxycet Component Oxycodone Hydrochloride

    38. Oxycodone Hydrochloride [usp Monograph]

    39. Roxicet Component Oxycodone Hydrochloride

    40. Roxilox Component Oxycodone Hydrochloride

    41. Troxyca Component Oxycodone Hydrochloride

    42. Combunox Component Oxycodone Hydrochloride

    43. Oxycodone Hydrochloride Component Of Tylox

    44. Percocet Component Oxycodone Hydrochloride

    45. Percodan Component Oxycodone Hydrochloride

    46. Roxiprin Component Oxycodone Hydrochloride

    47. Targiniq Component Oxycodone Hydrochloride

    48. Xartemis Component Oxycodone Hydrochloride

    49. Oxycodone Hydrochloride Component Of Codoxy

    50. Oxycodone Hydrochloride Component Of Oxycet

    51. Oxycodone Hydrochloride Component Of Roxicet

    52. Oxycodone Hydrochloride Component Of Roxilox

    53. Oxycodone Hydrochloride Component Of Troxyca

    54. Oxycodone Hydrochloride Component Of Combunox

    55. Oxycodone Hydrochloride Component Of Percocet

    56. Oxycodone Hydrochloride Component Of Percodan

    57. Oxycodone Hydrochloride Component Of Roxiprin

    58. Oxycodone Hydrochloride Component Of Targiniq

    59. Oxycodone Hydrochloride Component Of Xartemis

    60. Percodan-demi Component Oxycodone Hydrochloride

    61. Q27107601

    62. Oxycodone Hydrochloride Component Of Percodan-demi

    63. 14-hydroxy-3-methoxy-17-methyl-4,5alpha-epoxymorphinan-6-one Hydrochloride

    64. Oxycodone Hydrochloride, European Pharmacopoeia (ep) Reference Standard

    65. Oxycodone Hydrochloride, United States Pharmacopeia (usp) Reference Standard

    66. (5?)-4,5-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride

    67. (5alpha,17s)-14-hydroxy-3-methoxy-17-methyl-6-oxo-4,5-epoxymorphinan-17-ium Chloride

    68. 4,5.alpha.-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one Hydrochloride

    69. Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, Hydrochloride, (5.alpha.)-

    70. Oxycodone Hydrochloride Solution, 1.0 Mg/ml In Methanol, Analytical Standard, For Drug Analysis

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 351.8 g/mol
    Molecular Formula C18H22ClNO4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count1
    Exact Mass351.1237359 g/mol
    Monoisotopic Mass351.1237359 g/mol
    Topological Polar Surface Area59 Ų
    Heavy Atom Count24
    Formal Charge0
    Complexity553
    Isotope Atom Count0
    Defined Atom Stereocenter Count4
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameOxecta
    Drug LabelOXECTA (oxycodone HCl, USP) tablets are an immediate-release opioid analgesic intended for oral administration only. OXECTA contains oxycodone HCl, USP as the active analgesic ingredient. The tablets are round, convex, white and debossed with the str...
    Active IngredientOxycodone hydrochloride
    Dosage FormTablet
    RouteOral
    Strength7.5mg; 5mg
    Market StatusPrescription
    CompanyAcura Pharms

    2 of 4  
    Drug NameOxycodone hydrochloride
    Drug LabelDESCRIPTIONOxyContin (oxycodone hydrochloride controlled-release) Tablets are an opioid analgesic supplied in 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, and 160 mg tablet strengths for oral administration...
    Active IngredientOxycodone hydrochloride
    Dosage FormTablet, extended release; Tablet; Capsule; Solution
    Routeoral; Oral
    Strength30mg; 100mg/5ml; 15mg; 5mg; 10mg; 5mg/5ml; 80mg; 40mg; 20mg
    Market StatusTentative Approval; Prescription
    CompanyCorepharma; Vintage Pharms; Amneal Pharms; Impax Pharms; Aurolife Pharma; Avanthi; Teva; Endo Pharms; Sun Pharm Inds; Coastal Pharms; Rhodes Pharms; Mallinckrodt; Roxane; Lannett Holdings; Nesher Pharms; Vistapharm; Actavis Elizabeth; Lehigh Valley; Alvog

    3 of 4  
    Drug NameOxecta
    Drug LabelOXECTA (oxycodone HCl, USP) tablets are an immediate-release opioid analgesic intended for oral administration only. OXECTA contains oxycodone HCl, USP as the active analgesic ingredient. The tablets are round, convex, white and debossed with the str...
    Active IngredientOxycodone hydrochloride
    Dosage FormTablet
    RouteOral
    Strength7.5mg; 5mg
    Market StatusPrescription
    CompanyAcura Pharms

    4 of 4  
    Drug NameOxycodone hydrochloride
    Drug LabelDESCRIPTIONOxyContin (oxycodone hydrochloride controlled-release) Tablets are an opioid analgesic supplied in 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, and 160 mg tablet strengths for oral administration...
    Active IngredientOxycodone hydrochloride
    Dosage FormTablet, extended release; Tablet; Capsule; Solution
    Routeoral; Oral
    Strength30mg; 100mg/5ml; 15mg; 5mg; 10mg; 5mg/5ml; 80mg; 40mg; 20mg
    Market StatusTentative Approval; Prescription
    CompanyCorepharma; Vintage Pharms; Amneal Pharms; Impax Pharms; Aurolife Pharma; Avanthi; Teva; Endo Pharms; Sun Pharm Inds; Coastal Pharms; Rhodes Pharms; Mallinckrodt; Roxane; Lannett Holdings; Nesher Pharms; Vistapharm; Actavis Elizabeth; Lehigh Valley; Alvog

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Analgesics, Opioid

    Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)

    Narcotics

    Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Opioid Agonist [EPC]; Full Opioid Agonists [MoA]

    API SUPPLIERS

    read-more
    read-more

    01

    Veranova

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Chemoutsourcing
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothVeranova: A CDMO that manages complexity with confidence.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-06-21

    Pay. Date : 2014-06-13

    DMF Number : 18472

    Submission : 2005-06-30

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2005-036 - Rev 04

    Issue Date : 2024-04-10

    Type : Chemical

    Substance Number : 1793

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 49812-0150

    Start Marketing Date : 2010-06-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : Samung Industry Co., Ltd.

    Registration Date : 2019-12-23

    Registration Number : 20191223-209-J-267

    Manufacturer Name : Macfarlan Smith Ltd.

    Manufacturer Address : 10 Wheatfield Road, Edinburgh, EH11 2QA, United Kingdom

     VMF ROW, CN arrow-down
    ✖
    Available Reg Filing : ROW, CN
    AUDIT arrow-down
    Veranova

    02

    Rusan Pharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Milan
    Booth #5B137
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Rusan Pharma

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    EUROAPI

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    IOPC 2026
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2008-249 - Rev 04

    Issue Date : 2025-10-20

    Type : Chemical

    Substance Number : 1793

    Status : Valid

     JDMF EU-WC NDC KDMF VMF CN arrow-down
    ✖
    Available Reg Filing : CN
    AUDIT arrow-down
    EUROAPI Compnay Banner

    04

    Temad Co

    Iran

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTemad- We think of world-class quality.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2018-02-19

    Valid Till : 2019-02-19

    Written Confirmation Number : 665/149786

    Address of the Firm :

    NDC KDMF VMF Others AUDIT
    Temad

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Noramco

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-04-16

    Pay. Date : 2013-04-05

    DMF Number : 16399

    Submission : 2003-02-03

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2011-284 - Rev 02

    Issue Date : 2021-02-24

    Type : Chemical

    Substance Number : 1793

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 51634-0003

    Start Marketing Date : 2008-02-21

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : Samung Industry Co., Ltd.

    Registration Date : 2024-01-26

    Registration Number : 20240126-209-J-1599

    Manufacturer Name : Noramco, LLC

    Manufacturer Address : 500 Swedes Landing Road Wilmington, Delaware 19801

     VMF Others AUDIT
    Noramco

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Siegfried AG

    Switzerland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    American Chemical Society
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSiegfried – A global CDMO delivering integrated pharmaceutical development and manufacturing solutions.

    Contact Supplier Contact Supplier
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2006-001 - Rev 01

    Issue Date : 2018-11-21

    Type : Chemical

    Substance Number : 1793

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 0792-2936

    Start Marketing Date : 2010-02-04

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT arrow-down
    Company Banner

    07

    Veranova

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Chemoutsourcing
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothVeranova: A CDMO that manages complexity with confidence.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 32506

    Submission : 2018-03-16

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Nosa Chemical Co., Ltd.

    Registration Date : 2019-12-23

    Registration Number : 20191223-209-J-267(2)

    Manufacturer Name : Macfarlan Smith Ltd.

    Manufacturer Address : 10 Wheatfield Road, Edinburgh, EH11 2QA, United Kingdom

     VMF ROW, CN arrow-down
    ✖
    Available Reg Filing : ROW, CN
    AUDIT arrow-down
    Veranova

    08

    Veranova

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Chemoutsourcing
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothVeranova: A CDMO that manages complexity with confidence.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 34028

    Submission : 2019-10-14

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Baeksu Pharmaceutical Co., Ltd.

    Registration Date : 2019-12-23

    Registration Number : 20191223-209-J-267(A)

    Manufacturer Name : Macfarlan Smith Limited

    Manufacturer Address : 10 Wheatfield Road, Edinburgh, EH11 2QA, United Kingdom

     VMF ROW, CN arrow-down
    ✖
    Available Reg Filing : ROW, CN
    AUDIT arrow-down
    Veranova

    09

    Noramco

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2012-12-27

    Pay. Date : 2012-11-23

    DMF Number : 20975

    Submission : 2007-10-26

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2009-058 - Rev 04

    Issue Date : 2022-05-12

    Type : Chemical

    Substance Number : 1793

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 51634-0002

    Start Marketing Date : 2000-01-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF arrow-down
    ✖

    Registrant Name : Mundipharma Korea Co., Ltd.

    Registration Date : 2022-01-13

    Registration Number : 20220113-209-J-1209

    Manufacturer Name : Noramco Coventry LLC

    Manufacturer Address : 498 Washington Street Coventry, Rhode Island 02816 USA

     VMF Others AUDIT
    Noramco

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Noramco

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothNoramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-02-15

    Pay. Date : 2012-11-23

    DMF Number : 21353

    Submission : 2008-02-21

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Noramco

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Ensysce Biosciences Secures Second Financing to Advance Pain Programs from 2025 Agreement

    Details:

    PF614 (Oxycodone) is a controlled substance drug, which is currently being evaluated in Phase III clinical studies for the treatment of chronic pain.


    Lead Product(s): Oxycodone Hydrochloride,Inapplicable

    Therapeutic Area: Neurology Brand Name: PF614

    Study Phase: Phase IIIProduct Type: Controlled Substance

    Sponsor: Undisclosed

    Deal Size: $20.0 million Upfront Cash: Undisclosed

    Deal Type: Financing April 07, 2026

    blank

    01

    Ensysce Biosciences

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Ensysce Biosciences

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Oxycodone Hydrochloride,Inapplicable

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : $20.0 million

    Deal Type : Financing

    DEALS_DEV arrow-down

    Ensysce Biosciences Secures Second Financing to Advance Pain Programs from 2025 Agreement

    Details : PF614 (Oxycodone) is a controlled substance drug, which is currently being evaluated in Phase III clinical studies for the treatment of chronic pain.

    Product Name : PF614

    Product Type : Controlled Substance

    Upfront Cash : Undisclosed

    April 07, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After Primary Total Knee And Total Hip Arthroplasty

    Details:

    Oxycodone HCl is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pain, Postoperative.


    Lead Product(s): Tramadol Hydrochloride,Oxycodone Hydrochloride

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 03, 2025

    blank

    02

    Mayo Clinic

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Mayo Clinic

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tramadol Hydrochloride,Oxycodone Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Efficacy And Safety Of Tramadol And Oxycodone Versus Oxycodone Monotherapy For Pain Control After ...

    Details : Oxycodone HCl is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pain, Postoperative.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    September 03, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Protega’s ROXYBOND™ Gets FDA Approval As Abuse-Deterrent Pain Management Option

    Details:

    Roxybond (oxycodone HCl) is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.


    Lead Product(s): Oxycodone Hydrochloride,Inapplicable

    Therapeutic Area: Neurology Brand Name: Roxybond

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 29, 2024

    blank

    03

    Protega Pharmaceuticals

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Protega Pharmaceuticals

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Oxycodone Hydrochloride,Inapplicable

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Protega’s ROXYBOND™ Gets FDA Approval As Abuse-Deterrent Pain Management Option

    Details : Roxybond (oxycodone HCl) is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

    Product Name : Roxybond

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 29, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

    Details:

    Gabapentin Enacarbil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Substance-Related Disorders.


    Lead Product(s): Gabapentin Enacarbil,Oxycodone Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 08, 2024

    blank

    04

    Arbor Pharmaceuticals

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Arbor Pharmaceuticals

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Gabapentin Enacarbil,Oxycodone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioi...

    Details : Gabapentin Enacarbil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Substance-Related Disorders.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    February 08, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum

    Details:

    Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Funnel Chest.


    Lead Product(s): Bupivacaine,Oxycodone Hydrochloride

    Therapeutic Area: Musculoskeletal Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Miscellaneous

    Sponsor: AtriCure

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 16, 2023

    blank

    05

    Zuyderland Medisch Centrum

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Zuyderland Medisch Centrum

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Bupivacaine,Oxycodone Hydrochloride

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : AtriCure

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Intercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatum

    Details : Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Funnel Chest.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    February 16, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

    Details:

    NYX-783 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Opioid-Related Disorders.


    Lead Product(s): NYX-783,Oxycodone Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 07, 2022

    blank

    06

    Yale University

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Yale University

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : NYX-783,Oxycodone Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study

    Details : NYX-783 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Opioid-Related Disorders.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    July 07, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extraction

    Details:

    Oxycodone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.


    Lead Product(s): Oxycodone Hydrochloride,Ibuprofen

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 18, 2021

    blank

    07

    Eurofarma Laboratorios S.A

    Brazil
    arrow
    PEGS Boston Summit
    Not Confirmed

    Eurofarma Laboratorios S.A

    Brazil
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Oxycodone Hydrochloride,Ibuprofen

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extra...

    Details : Oxycodone is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 18, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    NanaBisâ„¢ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metasta...

    Details:

    Delta 9 Tetrahydrocannabinol is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cancer Pain.


    Lead Product(s): Delta 9 Tetrahydrocannabinol,Cannabidiol,Oxycodone Hydrochloride

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Undisclosed

    Sponsor: George Clinical | WriteSource Medical Pty Ltd

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 22, 2021

    blank

    08

    Medlab Clinical

    Australia
    arrow
    PEGS Boston Summit
    Not Confirmed

    Medlab Clinical

    Australia
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Delta 9 Tetrahydrocannabinol,Cannabidiol,Oxycodone Hydrochloride

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : George Clinical | WriteSource Medical Pty Ltd

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    NanaBisâ„¢ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD)...

    Details : Delta 9 Tetrahydrocannabinol is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cancer Pain.

    Product Name : Undisclosed

    Product Type : Undisclosed

    Upfront Cash : Inapplicable

    March 22, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operative Pain and Narcotic Pain Medication Requirements in ...

    Details:

    Oxycodone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain, Postoperative.


    Lead Product(s): Oxycodone Hydrochloride,Inapplicable

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 21, 2020

    blank

    09

    NYU Langone Health

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    NYU Langone Health

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Oxycodone Hydrochloride,Inapplicable

    Therapeutic Area : Neurology

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    An Analysis of the Efficacy of a Pre-Emptive Multimodal Pain Regimen in Reducing Acute Post-Operat...

    Details : Oxycodone is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain, Postoperative.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    August 21, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    S1916 Digital Medicine Program for Pain Control in Cancer Patients

    Details:

    Oxycodone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Neoplasms.


    Lead Product(s): Oxycodone Hydrochloride,Paracetamol

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Miscellaneous

    Sponsor: Proteus

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable December 11, 2019

    blank

    10

    SWOG Cancer Research Network

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    SWOG Cancer Research Network

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Oxycodone Hydrochloride,Paracetamol

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Proteus

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    S1916 Digital Medicine Program for Pain Control in Cancer Patients

    Details : Oxycodone is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    December 11, 2019

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - CAPSULE;ORAL - 5MG

    USFDA APPLICATION NUMBER - 200534

    read-more

    DOSAGE - SOLUTION;ORAL - 100MG/5ML

    USFDA APPLICATION NUMBER - 200535

    read-more

    DOSAGE - SOLUTION;ORAL - 5MG/5ML

    USFDA APPLICATION NUMBER - 200535

    read-more

    DOSAGE - SOLUTION;ORAL - 5MG/5ML **Federal Re...DOSAGE - SOLUTION;ORAL - 5MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 201194

    read-more

    DOSAGE - TABLET;ORAL - 5MG

    USFDA APPLICATION NUMBER - 202080

    read-more

    DOSAGE - TABLET;ORAL - 7.5MG

    USFDA APPLICATION NUMBER - 202080

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 325M...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 204031

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 13....DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 13.5MG

    USFDA APPLICATION NUMBER - 208090

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 18M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 18MG

    USFDA APPLICATION NUMBER - 208090

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 27M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 27MG

    USFDA APPLICATION NUMBER - 208090

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 36M...DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 36MG

    USFDA APPLICATION NUMBER - 208090

    read-more

    DOSAGE - CAPSULE, EXTENDED RELEASE;ORAL - 9MG

    USFDA APPLICATION NUMBER - 208090

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 10MG

    USFDA APPLICATION NUMBER - 22272

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 15MG

    USFDA APPLICATION NUMBER - 22272

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 20MG

    USFDA APPLICATION NUMBER - 22272

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 30MG

    USFDA APPLICATION NUMBER - 22272

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 40MG

    USFDA APPLICATION NUMBER - 22272

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 60MG

    USFDA APPLICATION NUMBER - 22272

    read-more

    DOSAGE - TABLET, EXTENDED RELEASE;ORAL - 80MG

    USFDA APPLICATION NUMBER - 22272

    read-more

    DOSAGE - TABLET;ORAL - 325MG;5MG **Federal Re...DOSAGE - TABLET;ORAL - 325MG;5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

    USFDA APPLICATION NUMBER - 87003

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Topical

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    01

    Rochem International Inc

    U.S.A
    arrow
    CPhI China
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Brand Name : Xanthan Gum

    Application : API Stability Enhancers, Thickeners and Stabilizers

    Excipient Details : Xanthan gum, a polysaccharide widely used in many industries as a food additive, thickening agent and stabilizer in topical formulations.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : Xanthan Gum

    arrow
    Xanthan Gum

    Excipients Web Link

    Virtual Booth

    02

    Pharm-RX Chemical

    U.S.A
    arrow
    SupplySide West
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothPharm-Rx is a reputed global importer and distributor of pharmaceutical active ingredients.

    Brand Name : Xanthan Gum

    Application : API Stability Enhancers, Thickeners and Stabilizers

    Excipient Details : Xanthan gum is widely used in oral dosage forms as a suspending and thickening agent. It is also used in topical formulations as a stabilizer.

    Pharmacopoeia Ref : NA

    Technical Specs : NA

    Ingredient(s) : Xanthan Gum

    arrow
    Pharm-Rx Xanthan Gum

    Excipients Web Link

    Virtual Booth

    03

    Dr. Paul Lohmann GmbH & Co. KGaA

    Germany
    arrow
    PCI Days
    Booth #C.13
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDr. Paul Lohmann® provides premium mineral salts backed by 140+ years of innovation, quality manufacturing, and global expertise.

    Dosage Form : Solution

    Grade : Oral

    Category : API Stability Enhancers

    Brand Name : Citric Acid 1-Hydrate

    Application : API Stability Enhancers

    Excipient Details : Citric Acid 1-hydrate is used as a chelating and/or complexing agent in various oral liquid formulations.

    Pharmacopoeia Ref : Ph. Eur.|USP

    Technical Specs : Not Available

    Ingredient(s) : Citric Acid Excipient

    arrow
    Citric Acid 1-Hydrate

    Excipients Web Link

    Virtual Booth

    04

    Dr. Paul Lohmann GmbH & Co. KGaA

    Germany
    arrow
    PCI Days
    Booth #C.13
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDr. Paul Lohmann® provides premium mineral salts backed by 140+ years of innovation, quality manufacturing, and global expertise.

    Dosage Form : Capsule, Solution, Tablet

    Grade : Oral

    Category : API Stability Enhancers, Lubricants & Glidants

    Brand Name : Sodium Benzoate

    Application : API Stability Enhancers, Lubricants & Glidants

    Excipient Details : Sodium Benzoate is used as a antimicrobial preservative in oral liquid dosage forms.

    Pharmacopoeia Ref : Ph. Eur.|NF

    Technical Specs : Not Available

    Ingredient(s) : Sodium Benzoate Excipient

    arrow
    Sodium Benzoate

    Excipients Web Link

    Virtual Booth

    05

    Dr. Paul Lohmann GmbH & Co. KGaA

    Germany
    arrow
    PCI Days
    Booth #C.13
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDr. Paul Lohmann® provides premium mineral salts backed by 140+ years of innovation, quality manufacturing, and global expertise.

    Dosage Form : Cream / Lotion / Ointment, Solution

    Grade : Oral

    Category : API Stability Enhancers, Topical

    Brand Name : Trisodium Citrate Anhydrous

    Application : API Stability Enhancers, Topical

    Excipient Details : Trisodium Citrate, anhydrous is used as an emollient in various semi-solid topical formulations. It is also used as a pH-modifier in oral liquids.

    Pharmacopoeia Ref : USP

    Technical Specs : Not Available

    Ingredient(s) : Trisodium Citrate Excipient

    arrow
    Trisodium Citrate Anhydrous

    Excipients Web Link

    Virtual Booth

    06

    Dr. Paul Lohmann GmbH & Co. KGaA

    Germany
    arrow
    PCI Days
    Booth #C.13
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDr. Paul Lohmann® provides premium mineral salts backed by 140+ years of innovation, quality manufacturing, and global expertise.

    Dosage Form : Solution

    Grade : Oral

    Category : API Stability Enhancers

    Brand Name : Disodium Phosphate 2-Hydrate

    Application : API Stability Enhancers

    Excipient Details : Disodium Phosphate 2-hydrate is used as a pH-Modifier (Acidifying/Alkalizing Agent/Buffering Agent) in various oral liquid dosage forms.

    Pharmacopoeia Ref : Ph. Eur.|USP

    Technical Specs : Not Available

    Ingredient(s) : Disodium Phosphate Dihydrate Excipient

    arrow
    Disodium Phosphate 2-hydrate

    Excipients Web Link

    Virtual Booth

    07

    Dr. Paul Lohmann GmbH & Co. KGaA

    Germany
    arrow
    PCI Days
    Booth #C.13
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDr. Paul Lohmann® provides premium mineral salts backed by 140+ years of innovation, quality manufacturing, and global expertise.

    Dosage Form : Solution

    Grade : Oral

    Category : API Stability Enhancers

    Brand Name : Trisodium Citrate 5.5-Hydrate

    Application : API Stability Enhancers

    Excipient Details : Trisodium Citrate 5.5-hydrate is used as a pH-modifier in oral liquid dosage forms.

    Pharmacopoeia Ref : Ph. Eur.|USP

    Technical Specs : Not Available

    Ingredient(s) : Trisodium Citrate Excipient

    arrow
    Trisodium Citrate 5.5-hydrate

    Excipients Web Link

    Virtual Booth

    08

    Dr. Paul Lohmann GmbH & Co. KGaA

    Germany
    arrow
    PCI Days
    Booth #C.13
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDr. Paul Lohmann® provides premium mineral salts backed by 140+ years of innovation, quality manufacturing, and global expertise.

    Dosage Form : Cream / Lotion / Ointment, Solution

    Grade : Oral

    Category : API Stability Enhancers, Topical

    Brand Name : Trisodium Citrate 2-Hydrate

    Application : API Stability Enhancers, Topical

    Excipient Details : Trisodium Citrate 2-hydrate is used as a emollient & pH-modifier in oral liquid dosage forms.

    Pharmacopoeia Ref : Ph. Eur.|USP

    Technical Specs : Not Available

    Ingredient(s) : Sodium Citrate Dihydrate Excipient

    arrow
    Trisodium Citrate 2-hydrate

    Excipients Web Link

    Virtual Booth

    09

    Gangwal Chemicals

    India
    PEGS Boston Summit
    Not Confirmed
    arrow

    10

    Shanghai Shenmei Pharmaceutical Te...

    China
    PEGS Boston Summit
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view

    Emulsifying Agents

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    APIs

    read-more
    read-more
    unitedkingdom_new.png
    Oxycodone (5 MT/ annum) API needed in United Kingdom [ENA23444]
    A company that focuses on the manufacturing of various finished formulations is looking for suppliers of Oxycodone (5 MT/ annum) API for commercial purposes. The suppliers must support this enquiry with CEP & CoA.
    07 Jul 2025

    Reply

    07 Jul 2025

    Reply text-arrow

    Reply Comment (7)

    07 Jul 2025

    india-flag.png
    Oxycodone (1 kg - 2 kg) API needed in India [ENA22434]
    A formulation development company that focuses on injectables, ophthalmics, semi-solids, and liquid oral-based products is looking for suppliers of Oxycodone (1 kg - 2 kg) API for development purposes. The suppliers must support this enquiry with USDMF, CEP & CoA.
    25 Mar 2025

    Reply

    25 Mar 2025

    Reply text-arrow

    Reply Comment (2)

    25 Mar 2025

    United_States_of_America.png
    Oxycodone HCl API needed in the U.S.A [ENA21987]
    A company that focuses on the development and manufacturing of various pharmaceutical products is looking for suppliers of Oxycodone HCl API for both development and commercial purposes. The suppliers must support this enquiry with USDMF & CoA.
    06 Feb 2025

    Reply

    06 Feb 2025

    Reply text-arrow

    Reply Comment (3)

    06 Feb 2025

    Iran.png
    Oxycodone HCl (400 kg/ annum) API needed in Iran [ENA20298]
    A company that focuses on manufacturing of various active pharmaceutical ingredient and finished dosage formulations is looking for suppliers of Oxycodone HCl (400 kg/ annum) API for commercial purposes. The suppliers must support this enquiry with GMP & CoA.
    17 Aug 2024

    Reply

    17 Aug 2024

    Reply text-arrow

    Reply Comment (10)

    17 Aug 2024

    Russia-big.png
    Oxycodone HCl (136 kg) API needed in Russia [ENA19989]
    A company that focuses on development and manufacturing of various finished formulations and medical devices is looking for suppliers of Oxycodone HCl (136 kg) API for commercial purposes. The suppliers must support this enquiry with CoA.
    16 Jul 2024

    Reply

    16 Jul 2024

    Reply text-arrow

    Reply Comment (14)

    16 Jul 2024

    india-flag.png
    Oxycodone HCl (25 kg) API needed in India [ENA19426]
    A company that focuses on distribution of various pharmaceutical products is looking for suppliers of Oxycodone HCl (25 kg) API for commercial purposes. The suppliers must support this enquiry with CoA.
    27 Apr 2024

    Reply

    27 Apr 2024

    Reply text-arrow

    Reply Comment (1)

    27 Apr 2024

    india-flag.png
    Ph. Eur Grade Oxycodone HCl API needed in India [ENA16325]
    A company that focuses on the development & manufacturing of oral solids and injectables is looking for suppliers of Ph. Eur Grade Oxycodone HCl API. The initial quantity is 4 kg for development & later 120 kg for commercial purposes. The suppliers must support this enquiry with CEP & CoA.
    07 Feb 2023

    Reply

    07 Feb 2023

    Reply text-arrow

    Reply Comment (7)

    07 Feb 2023

    india-flag.png
    Oxycodone HCl (500 g) API needed in India [ENA13823]
    A formulation development company that focuses on injectables, ophthalmics, semi-solids, and liquid oral-based products is looking for suppliers of Oxycodone HCl (500 g) API for development purpose. The suppliers must support this enquiry with USDMF, EUDMF, CEP, GMP & CoA.
    31 May 2022

    Reply

    31 May 2022

    Reply text-arrow

    Reply Comment (3)

    31 May 2022

    Egypt.png
    Various APIs needed in Egypt [ENA13339]
    A company that deals in manufacturing of veterinary & agri products is looking for suppliers of Various APIs for development purpose. The suppliers must support this enquiry with CoA. 1. Naltrexone Hydrochloride (10 g - 25 g) API 2. Oxycodone Hydrochloride (5 g - 10 g) API
    16 Apr 2022

    Reply

    16 Apr 2022

    Reply text-arrow

    Reply Comment (9)

    16 Apr 2022

    ElSalvador.png
    Oxycodone HCl & Methadone HCl APIs needed in El Salvador [ENA08637]
    A pharmaceutical company that deals in various segments such as antiseptics, dermatological, sweeteners, laxatives & vitamins is looking for suppliers of Oxycodone HCl & Methadone HCl APIs for development purposes. The required quantity is 500 g for each.
    24 Sep 2020

    Reply

    24 Sep 2020

    Reply text-arrow

    Reply Comment (17)

    24 Sep 2020

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Looking for 124-90-3 / Oxycodone Hydrochloride API manufacturers, exporters & distributors?

    Oxycodone Hydrochloride manufacturers, exporters & distributors 1

    64

    PharmaCompass offers a list of Oxycodone Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Oxycodone Hydrochloride manufacturer or Oxycodone Hydrochloride supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Oxycodone Hydrochloride manufacturer or Oxycodone Hydrochloride supplier.

    API | Excipient name

    Oxycodone Hydrochloride

    Synonyms

    124-90-3, Oxycodone hcl, Oxecta, Oxycontin, Endocodone, Roxicodone

    Cas Number

    124-90-3

    Unique Ingredient Identifier (UNII)

    C1ENJ2TE6C

    About Oxycodone Hydrochloride

    A semisynthetic derivative of CODEINE.

    Eukodal Manufacturers

    A Eukodal manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eukodal, including repackagers and relabelers. The FDA regulates Eukodal manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eukodal API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Eukodal manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

    Eukodal Suppliers

    A Eukodal supplier is an individual or a company that provides Eukodal active pharmaceutical ingredient (API) or Eukodal finished formulations upon request. The Eukodal suppliers may include Eukodal API manufacturers, exporters, distributors and traders.

    click here to find a list of Eukodal suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

    Eukodal USDMF

    A Eukodal DMF (Drug Master File) is a document detailing the whole manufacturing process of Eukodal active pharmaceutical ingredient (API) in detail. Different forms of Eukodal DMFs exist exist since differing nations have different regulations, such as Eukodal USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Eukodal DMF submitted to regulatory agencies in the US is known as a USDMF. Eukodal USDMF includes data on Eukodal's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Eukodal USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Eukodal suppliers with USDMF on PharmaCompass.

    Eukodal JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Eukodal Drug Master File in Japan (Eukodal JDMF) empowers Eukodal API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Eukodal JDMF during the approval evaluation for pharmaceutical products. At the time of Eukodal JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Eukodal suppliers with JDMF on PharmaCompass.

    Eukodal KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Eukodal Drug Master File in Korea (Eukodal KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Eukodal. The MFDS reviews the Eukodal KDMF as part of the drug registration process and uses the information provided in the Eukodal KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Eukodal KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Eukodal API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Eukodal suppliers with KDMF on PharmaCompass.

    Eukodal CEP

    A Eukodal CEP of the European Pharmacopoeia monograph is often referred to as a Eukodal Certificate of Suitability (COS). The purpose of a Eukodal CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Eukodal EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Eukodal to their clients by showing that a Eukodal CEP has been issued for it. The manufacturer submits a Eukodal CEP (COS) as part of the market authorization procedure, and it takes on the role of a Eukodal CEP holder for the record. Additionally, the data presented in the Eukodal CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Eukodal DMF.

    A Eukodal CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Eukodal CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Eukodal suppliers with CEP (COS) on PharmaCompass.

    Eukodal WC

    A Eukodal written confirmation (Eukodal WC) is an official document issued by a regulatory agency to a Eukodal manufacturer, verifying that the manufacturing facility of a Eukodal active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Eukodal APIs or Eukodal finished pharmaceutical products to another nation, regulatory agencies frequently require a Eukodal WC (written confirmation) as part of the regulatory process.

    click here to find a list of Eukodal suppliers with Written Confirmation (WC) on PharmaCompass.

    Eukodal NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Eukodal as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Eukodal API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Eukodal as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Eukodal and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Eukodal NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Eukodal suppliers with NDC on PharmaCompass.

    Eukodal GMP

    Eukodal Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Eukodal GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Eukodal GMP manufacturer or Eukodal GMP API supplier for your needs.

    Eukodal CoA

    A Eukodal CoA (Certificate of Analysis) is a formal document that attests to Eukodal's compliance with Eukodal specifications and serves as a tool for batch-level quality control.

    Eukodal CoA mostly includes findings from lab analyses of a specific batch. For each Eukodal CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Eukodal may be tested according to a variety of international standards, such as European Pharmacopoeia (Eukodal EP), Eukodal JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eukodal USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search